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Open Forum Infectious Diseases
REVIEW ARTICLE

Antibiotics for Preventing Recurrent Urinary Tract
Infection: Systematic Review and Meta-analysis
1
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3

Recurrent urinary tract infections are a common health problem. The only comprehensive synthesis on antibiotic prophylaxis in the
last 15 years has been a guideline-embedded meta-analysis. We conducted a systematic review and meta-analysis of randomized
controlled trials published up to October 13, 2020, evaluating patients age ≥12 years with either ≥2 episodes of lower urinary
tract infection (UTI) within 6 months or ≥3 in the past year. Placebo or antibiotics were allowed as comparators. Study quality
was low. In the 11 placebo-controlled trials, the risk for developing UTI was 85% lower with prophylaxis in comparison with
placebo (risk ratio [RR], 0.15; 95% CI, 0.08–0.29). In the 9 head-to-head trials, the efficacy of the antibiotic agents appeared
similar: The pooled RR indicated no difference between nitrofurantoin and comparators (RR, 1.01; 95% CI, 0.74–1.37), nor
trimethoprim (+/- sulfamethoxazole; RR, 1.34; 95% CI, 0.89–2.03) or norfloxacin and comparators (RR, 1.17; 95% CI, 0.43–
1.70). Studies comparing intermittent (postcoital) with continuous strategies revealed intermittent application to be equally
effective.
Keywords. antibiotic prophylaxis; recurrent urinary tract infection; meta-analysis; UTI; cystitis.
Urinary tract infections (UTIs) are a common health care prob
lem, with 11% of women reporting having suffered at least 1
UTI in the previous year [1]; 20%–30% of these women will ex
perience recurrent UTI (RUTI) [2]. In men, RUTIs are less
common, often associated with prostatic hyperplasia, and gen
erally not well studied [3].
Besides nonantibiotic measures, different antibiotic prophy
laxis regimens have been studied as a strategy for RUTI preven
tion, like continuous or intermittent antibiotic prophylaxis and
prophylactic antibiotics after UTI-promoting events such as sex
ual intercourse. However, preferable antibiotic choices are poorly
characterized, and the scientific literature on RUTI prophylaxis
randomized trials has only been screened systematically in
the last 15 years in a guideline-embedded meta-analysis [4],
2 meta-analyses focusing on nitrofurantoin [5, 6], and 3 descrip
tive literature reviews without meta-analysis [7–9]. Reviews and
meta-analyses to date have not reported outcomes restricted to
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clinical recurrences, thereby including asymptomatic bacteriuria
as recurrences. The objective of this systematic review and metaanalysis was to systematically assess the efficacy and safety of an
tibiotic prophylaxis for the prevention of RUTI in adults.
METHODS

We conducted a systematic review and meta-analysis of pub
lished and unpublished randomized controlled trials (RCTs)
on antibiotic prophylaxis for recurrent urinary tract infections.
We have followed PRISMA reporting guidelines [10].
Data Sources and Searches

We used the search terms “recurrent” AND “urinary tract in
fection” OR “UTI” OR “cystitis,” AND “prophylaxis” OR “an
tibiotic,” among others. The Cochrane sensitivity-maximizing
filter to identify randomized trials was applied [11]. The search
syntax is reported in Supplementary Table 1. We screened
MEDLINE (from 1964), EMBASE (from 1988), the Cochrane
Library (CENTRAL), the website clinicaltrials.gov, and refer
ence lists of retrieved articles. The date of last search for all
sources was October 13, 2020.
Study Selection

Criteria for randomized controlled trials were participants
(men or women) aged ≥12 years with either ≥2 episodes of
lower UTI within the last 6 months or ≥3 in the course of
the past year. We included any type of prophylaxis schedule
(daily, weekly, monthly, or postcoital). The control group had
to have received placebo or a comparator antibiotic. We
Antibiotic Prevention of Recurrent Urinary Tract Infection • OFID • 1
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Data Extraction and Quality Assessment

The following information was collected with a data extraction
form and brought together in a database: study setting, study
population (age, comorbidities, prior treatment), trial design,
inclusion and exclusion criteria, description of the interven
tion(s), duration of the intervention(s), length of follow-up,
methods used to assess outcomes (urine culture, clinical evalu
ation), number of dropouts, specifics of data analysis, type of
outcomes collected, and results.
The quality of the included trials was assessed in terms of the
randomization process, internal validity, and external validity,
based on the criteria described by Guyatt et al. [12]. Three in
vestigators (J.M., J.B., A.A.) independently rated the risk of bias
using a modification of the Cochrane handbook quality assess
ment recommendations [11].
Types of Outcome Measures

The primary outcome was the number of UTI episodes during
the observed period of prophylaxis intake. Recurrences that fol
lowed the period of antibiotic intake were captured as a second
ary outcome, as well as adverse effects (AEs) of antibiotic
administration, stratified by severity: AEs leading to discontin
uation of the treatment were considered severe AEs; all others
were considered nonsevere.
Recurrences could be measured on the one hand using micro
biological criteria (microbiological recurrences), with confirma
tion by a positive urine culture of >100 000 bacteria/mL, or
using symptoms consistent with UTI, pyuria and positive urine
culture with >10 000 bacteria/mL. On the other hand, they
could be identified using the clinical criteria dysuria, pollakisu
ria, hesitancy, and/or frequency (clinical recurrences).
Analysis of Studies With Trimethoprim ± Sulfamethoxazole as
Comparator

Based on the study by Stamm et al. [13], who found trimethoprim
alone (TMP) and its co-formulation with sulfamethoxazole
2 • OFID • Jent et al

(TMP-SMZ) to be equally efficacious for UTI prevention, and sim
ilar findings in therapeutic and pediatric studies, the single com
pound and its combinations with sulfamethoxazole were
analyzed as 1 antibiotic group.
Data Synthesis and Analysis

For analysis, included studies were classified into 3 main
groups: “placebo-controlled studies” (PC), “head-to-head stud
ies” (HH), and “continuous vs intermittent approaches” (CI).
One study [14] differed from all other studies in terms of design
and is therefore discussed individually.
The meta-analysis of the PC studies was based on a compar
ison of pooled risk ratios (RRs) in the 2 arms. As microbial re
currences are now considered to be of minor relevance, a
subanalysis restricted to reported clinical recurrences in the in
cluded studies was performed.
HH prophylaxis comparisons were based on the number of
infections per person-year, also in terms of an RR calculation.
Heterogeneity was evaluated using the Q and I2 statistics and
considered to be significant if the P value using the chi-square
test was <.1 for Q and to be high if the I2 value was ≥75%.
Confidence intervals for I2 were based on the Higgins and
Thomson calculation [15]. All meta-analyses were performed
using the statistical package OpenMetaAnalyst utilizing the
meta and metafor packages in R (R Foundation for Statistical
Computing, Vienna, Austria), based on random- and
fixed-effects models. Where appropriate, the absolute risk re
duction (ARR) was used to calculate the number needed to
treat (NNT).
Publication bias was investigated using funnel plots [16, 17]
and the arcsine test [18]. A sensitivity analysis was added to in
vestigate the potential effects of publication bias based on the
trim and fill method [19] and the Copas selection model [20,
21] and using the metasens package in R.
RESULTS
Description of Studies

We retrieved 2105 studies from the search strategy. Of this se
lection, 2082 studies did not meet the inclusion criteria or were
excluded for reasons disclosed in Figure 1. The main character
istics of the included 23 RCTs (24 comparisons) are depicted in
Supplementary Table 2. The time frame of publication of the
included studies ranged from 1971 to 2014, with only 3 pub
lished in the past 20 years. Six trials studied cinoxacin, an ob
solete antibiotic. Patients for the studies were mainly
recruited in outpatient clinics (20/23 studies), in 1 study in pri
vate practices [22], and in another study from university stu
dents [14], whereas 1 study did not describe the study setting
[23]. Most studies only included women, while 2 studies also
allowed the inclusion of men [23, 24]. The prophylaxis period
was 6 months in 13/23 studies, 12 months in 9/23 studies, and 3
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excluded studies comparing an antibiotic with a nonantibiotic
compound (with the exception of placebo) and studies that in
cluded pregnant and breastfeeding women, patients with a his
tory of urological surgery, major urogenital abnormalities,
severe urinary incontinence, permanent urinary catheters, spi
nal cord lesions, immunosuppression, and neurogenic bladder
dysfunction or severe renal function impairment (glomerular
filtration rate <30 mL/min). Comorbidities like history of uro
lithiasis, mild renal impairment, diabetes mellitus, mild urinary
incontinence, minor urogenital abnormalities on pyelogram,
cystoscopy, or radiography, single kidney, and temporary in
dwelling catheters were not reasons for exclusion.
Two reviewers (J.B., J.M.) independently selected the studies,
applying inclusion and exclusion criteria. In case of disagree
ment, 1 of the coauthors was consulted.

months in 1 study [25]. Of note, some studies suspended the
prophylaxis as soon as there was a recurrence.
Risk of Bias and Methodological Quality

Supplementary Figure 1 gives an overview of the risk of bias of
included studies. Overall, study quality was low. For PC studies,
the funnel plot indicated potential publication bias
(Supplementary Figure 3), although this finding was not sup
ported by a formal test of asymmetry (Arcsine test: P = .49).
Heterogeneity, as measured by the I2 statistic, was moderate
at 57% (95% CI, 19.3%–76.6%), with the influence and contri
butions from each of the studies shown in the Baujat plot [26]
in Supplementary Figure 2. Excluding the studies with

cinoxacin, an obsolete antibiotic, the heterogeneity of the treat
ment effect between the studies was reduced (I2 = 22.9%; 0%–
64.5%).
To further explore the discrepancy between the funnel plot
and Arcsine test, an additional sensitivity analysis using a sim
ple trim-and-fill method and a Copas selection model was per
formed. The trim-and-fill approach (Supplementary Figure 5)
suggested adding 3 hypothetical studies to achieve relative sym
metry, resulting in a slightly higher risk ratio, but still within
the original confidence intervals for the random-effects model
(RR, 0.23; 95% CI, 0.14–0.35; for trim and fill; vs RR, 0.15; 95%
CI, 0.08–0.29). The Copas selection method (Supplementary
Figure 6) produced an estimate slightly closer to that from
Antibiotic Prevention of Recurrent Urinary Tract Infection • OFID • 3
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Figure 1. Study flowchart with reasons for exclusion of studies (not mutually exclusive). aIncluding overlap between studies with a placebo as well as an antibiotic com
parator. Abbreviations: RCT, randomized controlled trial; RUTI, recurrent urinary tract infection.

Funding of Studies

Only 8 of the 23 studies stated funding sources, 4/8 reported fi
nancial support from pharmaceutical companies, and 5/8 stud
ies had pills or capsules provided by the pharmaceutical
industry (Supplementary Table 3).
Effect of the Intervention

Table 1 summarizes the effect of interventions in the metaanalysis, divided by type of comparison. Further details are giv
en below.
Placebo-Controlled Studies (Antibiotic vs Placebo)

In the 11 PC studies [13, 24, 27–35] including 805 patients (746
with efficacy assessment), the risk ratio for developing UTI was
0.15 (95% CI, 0.08–0.29; P < .0001) with antibiotic prophylaxis
in comparison with placebo; the corresponding overall risk re
duction was 55% (weighted average NNT, 1.81; 95% CI, 1.67–
2.17), assuming relative homogeneity of the treatment effect
(Figure 2). In absolute numbers, in the prophylaxis arm of tri
als, recurrences occurred in 33/400 patients (8%) during the
observation period and in 225/346 patients (65%) in the place
bo arm. Since 2004 (last Cochrane meta-analysis on this subject

Table 1. Summary of the Meta-analyses on Antibiotic Prophylaxis for
Recurrent Urinary Tract Infections, Divided by Type of Comparison

Type of Comparison

No. of
Studies

No. of
Patients

Risk
Ratio

A. Placebo-controlled

11a

746

0.15

(0.08–0.29) <.001

A1. Placebo-controlled
excluding cinoxacinb

6

520

0.11

(0.07–0.17) <.001

B. Head-to-head

9a

636

B1. Nitrofurantoin vs other
antibiotic

7

486

1.01

(0.74–1.37)

.97

B2. TMP (± SMZ) vs other
antibiotic

4

176

1.34

(0.89–2.03)

.16

B3. Norfloxacin vs other
antibiotic

3

239

1.17

(0.43–1.70)

.66

C. Continuous vs
intermittent

3

564

1.78

(0.62–5.09)

.28

D. Intermittent vs placebo

1

25

0.15

(0.04–0.55)

.004

95% CI

P
Value

a

Stamm et al. [13] was included in the placebo-controlled comparison (trimethoprim ±
sulfamethoxazole vs placebo, nitrofurantoin vs placebo) and in the head-to-head
comparison (trimethoprim ± sulfamethoxazole vs nitrofurantoin).
Cinoxacin is an obsolete quinolone antibiotic.

4 • OFID • Jent et al

Head-to-Head Studies (Antibiotic vs Antibiotic)

A total of 9 HH trials [13, 23, 25, 38–43] with 766 patients (636
with efficacy assessment) comparing different prophylactic an
tibiotics were included. Nitrofurantoin was the single most
common comparator (to norfloxacin in 3 studies, to cefaclor
in 1 study, and to trimethoprim [± sulfamethoxazole] in 3 stud
ies); the pooled relative risk between nitrofurantoin and other
comparator antibiotics indicated no significant difference
(RR, 1.01; 95% CI, 0.74–1.37) (Supplementary Figure 7).
Trimethoprim (± sulfamethoxazole) was studied in 4 HH stud
ies, with no significant difference in the relative risk compared
with the comparator antibiotic (RR, 1.34; 95% CI, 0.89–2.03).
Similarly, there was no difference between norfloxacin and its
comparators (3 studies; RR, 1.17; 95% CI, 0.43–1.70).
Continuous vs Intermittent Studies (eg, Postcoital)

Abbreviations: SMZ, sulfamethoxazole; TMP, trimethoprim.

b

[36]), a single RCT comparing fosfomycin with placebo among
158 patients was published in 2005. This study reported an ab
solute UTI risk reduction of 68% (NNT, 1.5) [32]. The 6 RCTs
that remained after excluding cinoxacin (n = 5), an obsolete an
tibiotic, showed a comparable risk reduction of 61% (NNT,
1.64; RR, 0.11; 95% CI, 0.07–0.17). As microbial recurrences
nowadays are considered to be of minor relevance, a subanaly
sis restricted to reported clinical recurrences in placebocontrolled studies was performed (Figure 3). The risk ratio
for having a clinical recurrence was 0.11 with antibiotic pro
phylaxis (95% CI, 0.07–0.17); therefore, the prophylactic effect
against clinical recurrences was comparable to that against all
recurrences (including microbial recurrences as described
above).
A statistical analysis of UTI events after discontinuation of
prophylaxis was not possible due to inconsistent reporting of
the number of patients at risk in 2 of 3 studies that scrutinized
the postprophylaxis period: One of these 2 studies [24] drew the
conclusion that recurrences were infrequent even after discon
tinuation of prophylaxis, whereas the other reported no differ
ence in recurrences after discontinuation of prophylaxis as
compared with placebo [13]. The only study [37] that quanti
fied events after discontinuation of the prophylaxis and report
ed both the number of events and the number of patients at risk
found no difference in recurrences (59% in cinoxacin group,
39% in the placebo group, during a follow-up of ≥6 months af
ter ending prophylaxis). This analysis was limited by the small
number of included patients (n = 17 in the cinoxacin arm, 13 in
the placebo arm).

Three studies [22, 44, 45] including 596 patients (564 with effi
cacy assessment) compared a continuous antibiotic strategy
with intake of a prophylactic antibiotic dose either postinter
course [44] or after UTI-predisposing events such as micturi
tion, diarrhea, constipation, traveling, and taking long walks
[45]. One study in this group evaluated a monthly prophylactic
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the original model (P = .21; .13–.32), suggesting that 1 addi
tional study would be required to achieve symmetry. Thus,
the sensitivity analysis indicated consistent estimates of the
treatment effect with the original model.
For HH studies, there was little difference between the fixedand random-effects models, the funnel plot (Supplementary
Figure 4) was symmetric, and the formal test of asymmetry
was nonsignificant at the 5% level. A sensitivity analysis was
not deemed necessary in this case.

antibiotic dose without correlation to predisposing factors,
which was considered intermittent application [22]. Even in
cluding the latter approach, there was no significant difference
in efficacy between the continuous and intermittent prophylax
is approaches.
Intermittent (eg, Postcoital) vs Placebo Studies

Postcoital antibiotic prophylaxis compared with placebo was
only examined in 1 included study [14], and its effect was in
a comparable range (RR, 0.15; 95% CI, 0.04–0.55) to the
placebo-controlled continuous antibiotic prophylaxis trials
mentioned above.
Adverse Events

Reported adverse events (AEs) varied considerably in included
trials and were not reported at all in 1 study [24].
Supplementary Table 4 gives an overview of described AEs.
The pooled relative risk of nonsevere AEs with antibiotic pro
phylaxis was 3.42 (95% CI, 2.16–5.43; number needed to harm
[NNH], 7.89), and the pooled relative risk of severe AEs was
3.22 (95% CI, 1.32–7.89; NNH, 30.97), favoring placebo over
antibiotic prophylaxis.
The most commonly reported AEs with antibiotic prophy
laxis were gastrointestinal complaints (including nausea) and
oral or vaginal candidiasis. Allergic reactions or skin rashes
were reported in 7 RCTs, mostly in patients receiving antibiot
ics; however, skin rashes were also reported in patients receiv
ing placebo. Allergic reactions occurred with the following
antibiotics: norfloxacin (5 patients), cinoxacin (3), nitrofuran
toin (7), and trimethoprim-sulfamethoxazole/trimethoprim
(2). Skin rashes were described with cinoxacin (4), nitrofuran
toin (2), trimethoprim-sulfamethoxazole/trimethoprim (1),
cephalexin (1), fosfomycin (1), a nonidentifiable antibiotic
(5), and placebo (2).

Patients taking nitrofurantoin showed a higher number of
dropouts, even though the number of reported side effects in
the analyzed patients was comparable to that seen with other
antibiotics. This might indicate some underreporting in AEs
in the included studies, as an association of nitrofurantoin
with nonsevere AEs has been described before [5].
Neither renal insufficiency nor C. difficile enterocolitis was
mentioned as a possible AE in the included studies, also sug
gesting underreporting of AEs.
DISCUSSION

RUTIs are a common problem, causing morbidity and health
care costs. A variety of prophylactic options, including but
not limited to antibiotics, have been examined in either
head-to-head or placebo-controlled trials. Our analysis in
cludes 23 studies and confirms that antibiotic prophylaxis is ef
fective for RUTI prevention when compared with placebo, with
an NNT of only 1.81 (95% CI, 1.67–2.17). This finding is in line
with what was reported in the last 2 comprehensive compila
tions of studies on this subject by Albert et al. [36] and Anger
et al [4]. The NNT should be interpreted with caution though,
as event rates varied between studies. The effect seems to be
limited to the period of antibiotic intake [13, 24, 37], and the
optimal duration of antibiotic prophylaxis to balance the pre
ventive effect against potential toxicity or adverse effects re
mains unclear. Durations of prophylaxis >12 months have
not been studied in a controlled setting, although 1 case series
reported sustained efficacy over 5 years [46]. Head-to-head an
tibiotic comparisons were mainly published for nitrofurantoin
vs comparators and showed no significant difference in recur
rences, making nitrofurantoin, norfloxacin, and trimethoprimsulfamethoxazole essentially interchangeable options. The
strength of evidence on antibiotic interchangeability is
Antibiotic Prevention of Recurrent Urinary Tract Infection • OFID • 5
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Figure 2. Forest plot of placebo-controlled studies for antibiotic prophylaxis of recurrent urinary tract infections. aOr trimethoprim ± sulfamethoxazole. Abbreviation: RR,
risk ratio.

tempered by the fact that only 3 of the studies were published in
the past 20 years, and uropathogen resistance to fluoroquino
lones and trimethoprim-sulfamethoxazole has increased great
ly during that time period. In the small number of controlled
trials comparing intermittent UTI prophylaxis after an activity
that could precipitate UTI (such as sexual intercourse) vs con
tinuous prophylaxis, both strategies appeared to be equally
effective.
Of note, the systematically assessed study quality of the
included RCTs was low, indicating that the results of the
meta-analysis should be interpreted with caution. With studies
dating back as far as the 1970s, this may reflect a lower report
ing standard by today’s expectations rather than low study qual
ity. The placebo-controlled trial with the lowest methodological
quality [37] was the only included study that yielded indifferent
efficacy results, albeit with a very low rate of recurrence in both
arms.
When reviewing the inclusion criteria, it is noteworthy that
no uniform RUTI definition was employed in the included
studies. Over the years, the definition of RUTI has changed
from requiring 2 UTIs in the past 12 months (in earlier studies)
to 3 or more UTIs within 1 year (in later studies). Also, the end
points shifted from microbiological to clinical criteria, with the
latter now being considered more relevant. Earlier studies con
sidered asymptomatic bacteriuria to be the equivalent of a UTI.
In the 3 head-to-head trials by Brumfitt et al. [38–40], UTI re
currences were defined as the presence of clinical symptoms
without microbiological confirmation, and clinical recurrences
were 5 times more common than microbiological ones, sug
gesting that most patients did not have UTIs by current
definitions.
Antibiotic prophylaxis in RUTI prevention comes at a price,
on the one hand in the form of AEs such as drug toxicity and on
the other hand with the selection of antimicrobial resistance
and alterations to the patient’s microbiome. The considerable
number of reported AEs (NNH, 30.97 for severe AEs leading
6 • OFID • Jent et al

to discontinuation; NNH, 7.89 for nonsevere AEs), even
though there are indications of potential underreporting,
must be weighed against the potential benefit for a patient
when selecting a preventive strategy. Commonly reported
AEs such as vaginal candidiasis were classified as nonsevere if
they did not lead to discontinuation of prophylaxis, but may
from the patient’s perspective be just as undesirable as the pre
vented UTI episode.
Long-term antibiotic use is associated with resistance selec
tion. High rates of resistance development under prophylactic
antibiotics have been described for trimethoprimsulfamethoxazole in particular (eg, [47]). A recent study shed
light on the coexistence of antibiotic-resistant and -sensitive
strains within the intestinal tract as a reservoir and major
source for RUTI in a patient followed over a 5-year period us
ing genomic analysis of urine and fecal strains [48]. Resistance
development under prophylaxis complicates the treatment of
future UTI episodes and contributes to the corresponding bur
den in a community. This collateral effect has also to be taken
into consideration. Whether 1 antibiotic class is preferable to
others in terms of risk of inducing resistance cannot be deter
mined from this review; this should be clarified in future
studies.
Nonantibiotic options were not the focus of this metaanalysis and have been discussed in detail elsewhere [49–51].
Patient-initiated antibiotic therapy at UTI symptom onset as
an alternative to prophylaxis also has revealed satisfactory clin
ical response and low rates of overtreatment (treatment in
symptomatic episodes with consecutively negative urine cul
tures), as long as the patient population can manage selftreatment [2, 52, 53].
Further research in the form of well-planned randomized
controlled trials and long-term cohort studies is needed to clar
ify the role of antibiotic prophylaxis in relation to nonantibiotic
preventive options for RUTI and to define the optimal and safe
duration of antibiotic prophylaxis, taking into account the risk

Downloaded from https://academic.oup.com/ofid/article/9/7/ofac327/6628136 by Washington University at St Louis user on 30 November 2022

Figure 3. Forest plot of subanalysis of placebo-controlled studies restricted to reported clinical recurrences as events. aOr trimethoprim ± sulfamethoxazole. Abbreviation:
RR, risk ratio.

of resistance selection. For the time being, this meta-analysis
confirms that antibiotic prophylaxis is an effective prevention
strategy for RUTIs and that a number of antimicrobial sub
stances can be used with similar likelihood of success. The pro
phylactic effect seems, though, to be limited to the period of
antibiotic intake, and the effectiveness of antibiotic prophylaxis
should be weighed against concerns for resistance selection.

Supplementary materials Supplementary materials are available at Open
Forum Infectious Diseases online. Consisting of data provided by the au
thors to benefit the reader, the posted materials are not copyedited and
are the sole responsibility of the authors, so questions or comments should
be addressed to the corresponding author.
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